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Abstract: Tea has been consumed for thousands of years. Despite the different varieties, particular 
emphasis has been placed on green tea (GT), considering the associated health benefits following its 
regular consumption, some of which are due to its polyphenol constituents, such as epigallocate-
chin-3-gallate (EGCG). Tea is not prone to the growth of microorganisms, except fungus, when 
proper storage, handling, and packing conditions are compromised. Consequently, mycotoxins, sec-
ondary metabolites of fungi, could contaminate tea samples, affecting human health. In the present 
study, we aimed to assess the balance between risks (due to mycotoxins and high levels of EGCG) 
and benefits (due to moderate intake of EGCG) associated with the consumption of GT. For this, 20 
GT samples (10 in bulk and 10 in bags) available in different markets in Lisbon were analyzed 
through a LC–MS/MS method, evaluating 38 different mycotoxins. Six samples revealed detectable 
values of the considered toxins. Current levels of mycotoxins and EGCG intake were not associated 
with health concerns. Scenarios considering an increasing consumption of GT in Portugal showed 
that drinking up to seven cups of GT per day should maximize the associated health benefits. The 
present study contributes to the future establishment of GT consumption recommendations in Por-
tugal. 
Keywords: green tea; mycotoxins; polyphenols; EGCG; risk–benefit assessment 
Key Contribution: risks and benefits associated with the consumption of green tea were assessed 
in the present study. The obtained results showed that increasing green tea consumption up to 




Tea has been consumed for thousands of years. In Portugal, despite modest production, 
tea consumption is also increasing, mostly due to influences from other cultures [1]. The larg-
est tea producers in the world are China, India, Sri Lanka and Turkey, with China and India 
covering about 43% and 22% of the world’s production, respectively [2]. In Portugal, two main 
producers can be identified. These are located on the island of São Miguel, in Azores—one 
with larger scale production, named Gorreana, and another with a reduced production vol-
ume, called Porto Formoso [1]. 
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The most commonly consumed types of tea worldwide are black, white, oolong, green, 
and Puerh (postfermented) tea [3]. Due to healthy lifestyle trends associated with several de-
veloped studies that have indicated a wide variety of health benefits, green tea consumption 
has increased [4,5]. From the already claimed health benefits, several reports have already 
identified: the reduction in the occurrence of cardiovascular diseases [6], the inhibition of ma-
trix metalloproteinases [7], the use as stimulant, the regulation of body temperature and anti-
microbial activity [8], regulation of blood sugar, and promotion of digestion [9]. These health 
benefits are usually associated with green tea components such as vitamins, microelements, 
essential oils, and polyphenols [10]. From all these beneficial food components, polyphenols 
have received particular interest, being the most relevant the catechins and the flavonols. Pre-
vious authors have demonstrated that these polyphenols have the capacity to alter the patho-
genesis of some chronic diseases due to their antioxidant, anti-inflammatory, antiproliferative, 
antimutagenic, antibacterial, and antiviral characteristics providing protection against cardio-
vascular disease, hyperglycemia, metabolic disorders, and some cancers [11,12]. 
Catechins can be found in high concentrations in fresh tea leaves, rock-rose leaves, broad 
beans, red wine, black grapes, strawberries, and apricots [13]. However, the most important 
dietary source of catechins is green tea [14]. Regarding the antioxidant efficacy of catechins, it 
is important to mention that this efficacy is due to direct mechanisms—scavenging reactive 
oxygen species (ROS), chelating metal ions—and indirect mechanisms—inducing antioxidant 
enzymes, inhibiting pro-oxidant enzymes, and producing phase II detoxification enzymes 
(e.g., glutathione) and antioxidant enzymes (e.g., glutathione peroxidase) [14]. 
Catechins also have important roles in preventing oxidative stress-caused diseases such 
as cancer, neurodegenerative diseases—Parkinson’s disease and Alzheimer’s disease —cardi-
ovascular diseases, and diabetes, since all these diseases are linked to changes in oxidant–an-
tioxidant balances and free radical damage [15,16]. Therefore, due to their antioxidant prop-
erties, catechins may be particularly valuable in preventing and protecting from pathologies 
associated with oxidative stress [16,17]. However, green tea extracts, particularly (-)-epigallo-
catechin-3-gallate (EGCG), the most relevant catechin in green tea, have been associated with 
cases of hepatotoxicity. In 2018, a European Food Safety Authority (EFSA) panel indicated that 
there is scientific evidence from interventional clinical trials that the intake doses of EGCG 
equal or above 800 mg/day taken as a food supplement induce a statistically significant in-
crease in serum transaminases in treated subjects when compared with a control group [18]. 
Concerning microbiological contamination, it is expected that tea contains a reduced 
level of microorganisms due to its low water activity and, consequently, the reduced risk re-
lated to the growth of microorganisms [19]. However, inappropriate storage, handling, and 
packing conditions of tea can increase the possibility of fungal contaminations [20,21] and/or 
growth [3]. Indeed, microbial contamination was already observed in samples of bulk and 
bags of green tea marketed in Lisbon [22]. This study reported a significant reduction in bac-
terial contamination after boiling; however, fungal presence with toxigenic potential was re-
ported before and after boiling [22]. 
Additionally, mycotoxins can also be present in tea due to the fungal contamination. My-
cotoxins are natural toxins produced by specific fungi that can grow on a variety of harvests 
[23]. Mycotoxin production in tea can occur at any production stage such as tea bush cultiva-
tion, harvest, processing, and storage. Poor agricultural procedures, improper processing, 
drying, packaging, storage, and transport conditions stimulate fungal growth, increasing the 
risk of mycotoxin contamination [3,20]. 
A subtropical climate, being favorable for tea farming, is also adequate for toxigenic mold 
growth. Aflatoxins and ochratoxin A are two the most toxic mycotoxins already detected in 
tea samples, but fumonisins, deoxynivalenol, and enniatins have also been reported in previ-
ous studies [20,24]. 
Even when considering the beverage only, it is important to consider that several factors 
can influence the mycotoxin transfer from the raw tea such as the raw tea contamination level, 
mycotoxin thermal stability, and its ability to transfer from the matrix into aqueous infusions. 
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Definitely, brewing is incapable of destroying common mycotoxins in a substantial manner 
[25,26]. 
Nevertheless, mycotoxins in tea are not properly regulated, except in some countries—
namely, in Customs Union countries (Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Rus-
sia)—for aflatoxin B1 in raw tea (5 µg/kg); in Argentina, established limits for aflatoxin B1 (5 
µg/kg) and total aflatoxins in materials used for herbal tea infusions are 20 µg/kg [27]. Upper 
limits for a category such as “all foods” have been fixed in several Asian countries [3]. In the 
EU, a regulation setting the maximum levels for mycotoxins in foodstuffs does not specifically 
consider tea [28]. 
Over recent years, combined assessments of risks and benefits associated with different 
food components, such as, e.g., hazardous agents, nutrients, as well as single foods and whole 
diets, have been carried out, resulting in the establishment of “risk-benefit assessment” (RBA) 
as a new multidisciplinary and integrated scientific discipline [29–32]. The balance between 
risks and benefits established by the RBA is very relevant to the food-related authorities, con-
tributing to the development of food policies and consumer guidance and recommendations, 
to businesses developing new food products, and to consumers considering dietary changes 
[33]. 
Taking into account the potential health benefits associated with the consumption of 
green tea [4,18], mainly due to the intake of catechins, and the potential health risks due to 
mycotoxin contamination and/or high levels of intake of catechins, an adequate balance re-
garding these two aspects is needed. The present study intended to evaluate the occurrence 
levels of mycotoxins in green tea samples marketed in Portugal, to assess the balance between 
risks (due to mycotoxins and high levels of catechins) and benefits (due to moderate intake of 
catechins) associated with the consumption of green tea, and to assist future research regard-
ing the risk–benefit assessment of green tea, contributing to support consumption recommen-
dations of green tea in Portugal. 
2. Results 
2.1. Mycotoxins Occurrence in Tea Samples 
Twenty samples (10 bulk and 10 bag samples) were analyzed for the presence of myco-
toxins. In the bulk samples, five samples (50%) showed mycotoxin contamination (presenting 
at least one mycotoxin) and, in one of the samples, five mycotoxins were simultaneously de-
tected—namely, zearalenone (one sample, 9.0 ng/g), aflatoxin B1 (one sample, <2.4 ng/g), 
fumonisin B1 (one sample, 15.8 ng/g), mycophenolic acid (three samples, <16.2, 154.5 and 170.4 
ng/g), and sterigmatocystin (three samples, all <2.4 ng/g) (Figure 1). 
 
Figure 1. Number of bulk samples positive (above limit of detection (LOD)) for mycotoxins. 
In bag samples, only one mycotoxin (mycophenolic acid) was detected in six samples 
(60%). The values ranged between <16.2 (limit of detection (LOD)) and 66.8 ng/g. 
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2.2. Mycotoxins and Catechins Estimated Intake 
Table 1 summarizes the estimated intake of mycotoxins (aflatoxin B1 (AFB1), 
fumonisin B1 (FB1), zearalenone (ZEA), and sterigmatocystin (STER)) and catechins 
(EGCG) and the associated risk. Taking into consideration the reported consumption of 
green tea in Portugal (corresponding to the current situation), or the alternative scenarios 
considered in the present study (corresponding to the hypothetical situations), the prob-
able intake of mycotoxins and EGCG was calculated, as well as the risk associated with 
calculated level of exposure. 
Considering the current consumption of green tea in Europe (as described by the 
EFSA, 2018), the estimated levels of intake of mycotoxins ranged between 0.00002 (AFB1 
and STER) and 0.0019 ng/kg bw/day (FB1). For the hypothetical scenarios, the highest es-
timated intake was determined for FB1. Considering the associated risk, none of the cur-
rent and hypothetical scenarios revealed a level of intake that represents a concern for 
public health—i.e., Margins of exposure (MOEs) of AFB1 and STER intakes were all sig-
nificantly above 10,000 (highlighted in green in the Table 1); Hazard quotients (HQs) of 
FB1 and ZEA intakes were all significantly below 1 (highlighted in green in Table 1). 
Regarding catechins, EGCG estimated intake considering the current EU consump-
tion ranged between 86.0 and 321.2 mg/day. EGCG intakes in current consumption (for 
the minimum and maximum consumption levels) were below the reference level of no 
hepatotoxicity (800 mg/day), suggesting that these consumption levels are associated with 
the health benefits usually associated with the intake of catechins. However, for the hy-
pothetical scenarios higher than seven cups per day, it is expected that the intake levels of 
EGCG would exceed the referred no hepatotoxicity level, and consequently, should be 
avoided (highlighted in red in the Table 1). According to these results, seven cups of green 
tea correspond to the highest quantity that could be drunk without expecting health con-
sequences. 
Table 1. Estimated intake and associated risk of mycotoxins and catechins (epigallocatechin-3-gallate (EGCG)). High-
lighted values of risk (bold) represent intake above the levels considered as safe. A color code was used to express the 





Estimated Intake of  
Mycotoxins (ng/kg bw/Day) and Cate-
chins (mg/Day) 
Estimated Risk Associated with the Exposure to 
Mycotoxins and Catechins 
Current a  AFB1 FB1 ZEA STER EGCG c AFB1 d FB1 e ZEA e STER d EGCG f 
Minimum 122.8 0.00002 0.0005 0.0003 0.00002 86.0 17,445,715 0.000005 0.000001 6,978,285,900 11 
Maximum 458.9 0.00009 0.0019 0.0011 0.00009 321.2 4,669,857 0.000019 0.000004 1,867,942,679 40 
Hypothetical b            
1 cup/day 150 0.00003 0.0006 0.0004 0.00003 105 14,285,714 0.000006 0.000001 5,714,285,714 13 
2 cups/day 300 0.00006 0.0013 0.0007 0.00006 210 7,142,857 0.000013 0.000003 2,857,142,857 26 
3 cups/day 450 0.00008 0.0019 0.0011 0.00008 315 4,761,905 0.000019 0.000004 1,904,761,905 39 
4 cups/day 600 0.00011 0.0025 0.0014 0.00011 420 3,571,429 0.000025 0.000006 1,428,571,429 53 
5 cups/day 750 0.00014 0.0032 0.0018 0.00014 525 2,857,143 0.000032 0.000007 1,142,857,143 66 
6 cups/day 900 0.00017 0.0038 0.0022 0.00017 630 2,380,952 0.000038 0.000009 952,380,952 79 
7 cups/day 1050 0.00020 0.0044 0.0025 0.00020 735 2,040,816 0.000044 0.000010 816,326,531 92 
8 cups/day 1200 0.00022 0.0050 0.0029 0.00022 840 1,785,714 0.000050 0.000011 714,285,714 105 
9 cups/day 1350 0.00025 0.0057 0.0032 0.00025 945 1,587,302 0.000057 0.000013 634,920,635 118 
10 cups/day 1500 0.00028 0.0063 0.0036 0.00028 1050 1,428,571 0.000063 0.000014 571,428,571 131 
a According to the EFSA, 2018 [18]. b Scenarios of consumption hypothetically assumed. 1 cup of green tea = 150 g. c EGCG 
levels assumed in accordance with the EFSA, 2018 [18]. d Margin of exposure (MOE) approach. MOE = BMDL10/Exposure 
data. e Hazard quotient (HQ) approach. HQ = intake values/reference values. f Percentage of intake compared to the EGCG 
level of no hepatotoxicity, according to the EFSA, 2018 [18]. AFB1 = aflatoxin B1; FB1 = fumonisin B1; ZEA = zearalenone; 
STER = sterigmatocystin; EGCG = epigallocatechin-3-gallate. 
  




Generally, tea consists of polyphenols, caffeine, minerals, and trace levels of vita-
mins, amino acids, and carbohydrates [34]. From all the varieties of tea, green tea has 
gained particular relevance due to the significant health benefits assigned to its reach con-
tent in polyphenols (i.e., catechins and flavonols)—namely, through their antioxidant, 
anti-inflammation, anticancer, anticardiovascular, antimicrobial, antihyperglycemic, and 
antiobesity properties [35]. The health benefits of green tea, in particular EGCG, were 
widely investigated. In addition to green tea, EGCG can be found in chocolate (600 mg/L), 
red wine (300 mg/L), and fruits—e.g., apricots or cherries (250 mg/kg fresh weight) [36]. 
Catechins are also widespread in vegetables such as broad beans and plant-derived prod-
ucts such as wine [37]. Among all catechins that can be found in food, catechin (C), epi-
catechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and EGCG are the most 
prevalent. However, after brewing green tea, catechins could undergo conversion to suit-
able epimers, such as epigallocatechin (ECG) to gallocatechin (GC) and EGCG to gallocat-
echin gallate (GCG) [38]. 
Harmful effects of green tea overconsumption were also reported and are mainly due 
to three main reasons: its caffeine content, the presence of aluminum, and the effects of 
tea polyphenols on iron bioavailability [39]. Indeed, some studies revealed the ability of 
tea plants to accumulate high levels of aluminum [40]. Furthermore, green tea catechins 
may present an affinity for iron, and infusions can cause an important decrease in the iron 
bioavailability from the diet [41]. In 2018, Hu et al. performed a systematic review of pub-
lished toxicology and human intervention studies aiming to characterize potential haz-
ards associated with consumption of green tea and its preparations. In this study, a safe 
intake level of 338 mg EGCG/day was recognized for adults which was derived from tox-
icological and human safety data for tea preparations ingested as a solid bolus dose [42]. 
Recently, the EFSA has stated that, from the clinical studies reviewed, there is no 
evidence of hepatotoxicity below 800 mg EGCG/day up to 12 months [18]. The EFSA panel 
also concluded that catechins from green tea infusion, prepared in a traditional way, and 
reconstituted drinks with an equivalent composition to traditional green tea infusions are 
generally considered to be safe according to the presumption of safety approach consid-
ering the intake corresponding to the reported consumption in European Member States 
[18]. However, the health effects linked with this EGCG dosage (<800 mg EGCG/day up 
to 12 months) still need to be demonstrated. 
Although there are several publications in agreement with the long history of safe 
consumption of large quantities of green tea as a beverage by humans without any re-
ported negative health effects [42,43], with the current knowledge, some considerations 
concerning consumption rates should be highlighted. 
In the present study, the balance between risks (due to mycotoxins and high levels of 
EGCG) and benefits (due to moderate intake of EGCG) associated with the consumption 
of green tea was assessed in an attempt to shed light on the suitable consumption rates of 
green tea. In fact, in addition to the health effects induced by polyphenols usually present 
in green tea, other aspects should be considered in terms of the impact drinking this bev-
erage on consumers’ health. As evidenced in the present study, mycotoxins could con-
taminate green tea, constituting a human exposure source to mycotoxins [11]. Likewise, 
using a multimycotoxin LC–MS/MS method, Pallarés et al. (2017) analyzed 16 mycotoxins 
in 44 tea samples, including 10 samples of green tea [44]. Contrary to the results obtained 
in the present study, which shows the presence of five different mycotoxins, Pallarés et al. 
(2017) revealed that enniatin B was the only mycotoxin detected in the green tea samples 
analyzed (2 out of 10 samples) at levels below the quantification limits (limit of quantifi-
cation (LOQ) = 0.2 µg/L) [44]. Aflatoxins, deoxynivalenol, nivalenol, HT-2 and T-2 toxins, 
zearalenone, ochratoxin A, and beauvericin were not detected in any sample. Considering 
food supplements of green tea, Martínez-Domínguez et al. showed that the analyzed sam-
ples were contaminated by aflatoxin B1 (one positive sample, 5.4 µg/kg) [45]. Aflatoxins 
B2, G1, G2, deoxynivalenol, fumonisin B1 and B2, HT-2 and T-2 toxins, ochratoxin A, and 
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zearalenone were not detected in the considered samples [45]. It is important to mention 
in this context that the use of the LC–MS/MS technique (characterized by high sensitivity) 
in the presented study allowed for a significant simplification of the procedure of sample 
preparation. An additional advantage is the possibility of simultaneous determination of 
many mycotoxins belonging to different groups of compounds with different structures. 
Many mycotoxins determined with the use of conventional detectors, e.g., fluorescence, 
require chemical derivatization (e.g., aflatoxins, fumonisins). In tandem mass spectrome-
try, this step does not occur. Another advantage of using LC–MS/MS is obtaining addi-
tional identification points for a given compound, based not only on the chromatographic 
retention time, but also on the mass of precursor and product ions. The influence of matrix 
components on the measurement signal is the main disadvantage of using the LC–MS/MS 
technique in food analysis. Additional disadvantages are the associated high cost of pur-
chasing the equipment and the need to have qualified personnel to operate it. 
The results obtained in the present study revealed that the risk due to the current 
exposure to mycotoxins through green tea consumption in Portugal is not associated with 
health concern (MOE > 10,000 and HQ < 1 in the current estimated exposure). Neverthe-
less, interesting results were described by some authors regarding the potential protective 
effects of EGCG on the toxicity associated with mycotoxins. Marnewick et al. showed that 
green tea presented chemoprotective properties against cancer promotion induced by 
fumonisin B1 in rat liver [46]. Sugiyama et al. described protective effects of EGCG against 
the trichothecene-induced cytotoxicity in mouse macrophages [47]. These results, despite 
needing further investigation, suggest that green tea components such as EGCG could be 
useful in protection against the toxic effects of mycotoxins eventually present in this bev-
erage. Consequently, the low magnitude of risk identified in the present study could be 
even lower, if this referred potential protective effect of EGCG is confirmed. 
According to our findings, the major limiting aspect influencing the risk of increasing 
the consumption of green tea is the potential adverse effects associated with high intake 
of EGCG (>800 mg EGCG/day). The current consumption of green tea in Portugal, ranging 
between 122.8 (less than one cup per day) and 458.9 g/day (around three cups per day), is 
not associated with an intake of EGCG being a health concern. Increasing the consumption 
of green tea to up to seven cups per day (corresponding to 1050 g/day) is expected to not 
cause health concern, and simultaneously, should maximize the beneficial effects associ-
ated with EGCG. Here, we considered just two green tea components—i.e., mycotoxins 
and EGCG. However, and in order to support future recommendations regarding green 
tea consumption in Portugal, a full quantitative risk–benefit assessment, considering ad-
ditional components and the associated health effects, should be developed in the near 
future. However, and despite the uncertainties associated with the present assessment, 
mainly related with the low number of analyzed samples and EGCG levels not measured 
but assumed from the EFSA document [18], the present study opens the discussion to 
establish future research regarding the risk–benefit assessment of green tea, and conse-
quently contributing to the increase in green tea consumption in Portugal. 
4. Conclusions 
In addition to the quantification of the occurrence levels of mycotoxins, the present 
study also assessed the balance between risks (due to mycotoxins and high levels of cate-
chins) and benefits (due to moderate intake of catechins) associated with the consumption 
of green tea. Results evidenced that consumption of up to seven cups per day is expected 
to maximize the beneficial effects associated with green tea consumption, mainly associ-
ated with EGCG intake. Taking into consideration the potential beneficial effects, these 
results establish the basis for future research regarding the risk–benefit assessment of 
green tea as a tool contributing to support the definition of consumption recommenda-
tions of green tea. Future efforts should be dedicated to advancing the current evidence, 
through a full risk–benefit assessment, and subsequently support policy actions that aim 
to improve public health. 
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5. Materials and Methods 
5.1. Sample Collection 
Tea samples available to consumers were purchased from different markets in Lis-
bon. In order to ensure a representative sample of commercialized green tea, twenty dif-
ferent green tea samples were selected in different presentations: in bulk (10 samples) and 
in bags (10 samples). Considered samples were from seven different origins (China, Por-
tugal (Azores), England, Japan, Indonesia, Ceylon (Sri Lanka), and Nepal). 
5.2. Analytical Determination of Mycotoxins 
Tea samples (1.0 g) were shaken with 4.0 mL of ACN:H2O:AcOH (79:20:1) for 60 min. 
After centrifugation for 5 min at 5000 rpm, raw extracts (0.5 mL) were diluted with 0.5 mL 
of water, mixed, centrifuged, and analyzed by the LC–MS/MS technique. 
Mycotoxins were separated by a Nexera high performance liquid chromatograph 
(HPLC) (Shimadzu, Tokyo, Japan) using a Gemini C18 (150 × 4.6 mm, 5 µm) (Phenomenex, 
Torrance, CA, USA) chromatographic column with a flow rate of 1 mL/min and an injec-
tion volume of 5 µL. Mobile phases contained 5 mmol/L ammonium acetate and consisted 
of methanol/water/acetic acid 10/89/1 (v/v/v) (mobile phase A) and methanol/water/acetic 
acid 97/2/1 (v/v/v) (mobile phase B). The elution program was designed as follows: iso-
cratic profile until 2.0 min with 0% of B, then from 2.0 to 5.0 min increase the organic phase 
to 50%, from 5.0 to 14.0 min increase the organic phase to 100%, from 14.0 to 18.0 min 
isocratic profile at 100% of B, and finally, from 18.0 min column equilibration for 4.5 min 
at 0% of B. 
Mycotoxins were detected on a 5500 QTrap mass detector (Sciex, Foster City, CA, 
USA). Detection was performed in a single chromatographic run of both negative and 
positive polarities using scheduled Multiple Reaction Monitoring (sMRM) mode. The 
source parameters were as follows: curtain gas 30 psi, collision gas medium, ionspray 
voltage −4500 (negative polarity) and 5500 V (positive polarity), temperature 550 °C, ion 
source gas1 80 psi, and ion source gas2 80 psi. Mass spectrometry parameters of analyzed 
mycotoxins are presented in Table 2. 
Table 2. Selected precursor and product ions of the analyzed mycotoxins with the respective declustering potential, colli-
sion energy, and cell exit potential values. 








Cell Exit Potential 
(V) 
15-Acetyldeoxynivalenol [M+H]+ 339.1 321.2/137.2 91 13/17 18/8 
3-Acetyldeoxynivalenol [M+Ac]− 397.3 59.2/307.1 −70 −38/−20 −8/−7 
Aflatoxin B1 [M+H]+ 313.1 285.2/128.1 106 33/91 16/10 
Aflatoxin B2 [M+H]+ 315.1 287.2/259.2 96 37/43 18/18 
Aflatoxin G1 [M+H]+ 329.1 243.1/200.0 86 39/59 14/12 
Aflatoxin G2 [M+H]+ 331.1 313.2/245.2 111 35/43 18/14 
Aflatoxin M1 [M+H]+ 329.1 273.2/229.1 91 35/59 16/12 
α-Zearalanol [M−H]− 321.2 277.2/303.2 −115 −32/−30 −13/−15 
α-Zearalenol [M−H]− 319.2 160.1/130.1 −115 −44/−50 −13/−20 
β-Zearalanol [M−H]− 321.2 277.2/303.2 −115 −32/−30 −13/−15 
β-Zearalenol [M−H]− 319.2 160.0/130.0 −115 −44/−50 −13/−20 
Deepoxydeoxynivalenol [M+Ac]− 339.1 59.1/249.0 −70 −20/−18 −9/−17 
Deoxynivalenol [M+Ac]− 355.1 265.2/59.2 −70 −22/−40 −13/−8 
Diacetoxyscirpenol [M+NH4]+ 384.2 307.2/105.1 81 17/61 9/7 
DON-3- Glucosid [M+Ac]− 517.3 427.1/59.1 −80 −30/−85 −11/−7 
Fumonisin B1 [M+H]+ 722.5 334.4/352.3 121 57/55 4/12 
Fumonisin B2 [M+H]+ 706.5 336.4/318.4 126 59/51 8/2 
Fumonisin B3 [M+H]+ 706.5 336.3/318.5 126 59/51 8/2 
Fusarenon-X [M+Ac]− 413.2 59.1/263.0 −70 −44/−22 −9/−16 
Gliotoxin [M+H]+ 327.1 263.2/245.3 61 15/25 16/20 
Griseofulvin [M+H]+ 353.2 165.2/215.2 81 27/27 10/12 
HT-2 Toxin [[M+NH4]+ 442.2 263.1/345.1 76 21/27 19/20 
Mevinolin [M+H]+ 405.3 199.2/173.3 76 17/29 14/10 
Moniliformin [M−H]− 96.9 41.2 −100 −24 −5 
Monoacetoxyscirpenol [M+NH4]+ 342.2 265.1/307.2 71 13/13 26/8 
Mycophenolic acid [M+NH4]+ 338.1 207.2/303.2 61 33/19 16/18 
Neosolaniol [M+NH4]+ 400.2 215.0/185.0 76 25/29 12/14 
Nivalenol [M+Ac]− 371.1 281.1/59.1 −75 −22/−45 −15/−7 
Ochratoxin A [M+H]+ 404.0 239.0/102.0 91 37/105 16/14 
Ochratoxin B [M+H]+ 370.1 205.0/103.1 86 33/77 12/16 
Patulin [M−H]− 153.0 109.0/81.0 −50 −12/−18 −9/−11 
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Roquefortine C [M+H]+ 390.2 193.2/322.2 91 39/29 10/18 
Sterigmatocystin [M+H]+ 325.1 310.2/281.1 96 35/51 18/16 
T-2 Tetraol [M+NH4]+ 316.2 215.2/281.2 61 13/13 16/8 
T-2 Toxin [M+NH4]+ 484.3 215.2/185.1 56 29/31 18/11 
T-2 Triol [M+NH4]+ 400.2 281.3/215.2 71 13/17 16/12 
Zearalanone [M−H]− 319.2 205.2/107.0 −125 −34/−40 −13/−5 
Zearalenon [M−H]− 317.1 131.1/175.0 −110 −42/−34 −8/−13 
The detection (LOD) and quantification (LOQ) limits obtained for each mycotoxin 
are presented in Table 3. 
Table 3. Mycotoxins measured and respective limits of detection (LODs) and quantification 
(LOQs) (ng/g). 
Mycotoxins LOQ LOD 
15-Acetyldeoxynivalenol 75.0 22.5 
3-AcetylDON 22.9 6.9 
Aflatoxin B1 2.4 0.7 
Aflatoxin B2 1.5 0.5 
Aflatoxin G1 1.7 0.5 
Aflatoxin G2 3.1 0.9 
Aflatoxin M1 2.8 0.9 
Deepoxy-deoxynivalenol 63.1 19.0 
Deoxynivalenol 66.5 20.0 
Diacetoxyscirpenol 12.3 3.7 
DON Glucoside 31.5 9.5 
Fumonisin B1 42.4 12.7 
Fumonisin B2 24.0 7.2 
Fumonisin B3 29.9 9.0 
Fusarenon-X 49.2 14.8 
Gliotoxin 19.6 5.9 
Griseofulvin 9.9 3.0 
HT-2 Toxin 15.2 4.6 
Mevinolin 8.0 2.4 
Moniliformin 10.1 3.0 
Monoacetoxyscirpenol 15.1 4.5 
Mycophenolic acid 16.2 4.9 
Neosolaniol 6.5 1.9 
Nivalenol 35.1 10.5 
Ochratoxin A 2.6 0.8 
Ochratoxin B 4.2 1.3 
Patulin 73.4 22.1 
Roquefortine C 8.2 2.5 
Sterigmatocystin 2.4 0.7 
T2-Tetraol 32.8 9.8 
T2-Toxin 7.1 2.1 
T2-Triol 30.9 9.3 
Zearalanone 5.5 1.7 
Zearalenone 3.5 1.0 
α-Zearalanol 7.7 2.3 
α-Zearalenol 3.0 0.9 
β-Zearalanol 12.5 3.7 
β-Zearalenol 7.4 2.2 
5.3. Intake Assessment and Risk Estimates 
Intakes of mycotoxins and catechins (particularly EGCG, the most relevant catechin 
in green tea) were estimated considering: (i) the obtained mycotoxins occurrence data (for 
the detected mycotoxins); (ii) the EGCG levels in green tea (as reported by the EFSA, 2018 
[18]); (iii) European consumption data (for adults), both data according to the EFSA sci-
entific opinion on the safety of green tea catechins [18]. Additionally, different hypothet-
ical scenarios regarding the consumption of different number of cups (one cup of tea as-
sumed as 150 mL), were considered to compute the risk of increasing the consumption of 
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green tea, promoting the health benefits associated with catechins, avoiding risky values 
of exposure due to mycotoxin intake and/or excessive levels of catechins. 
The instructions presented in the label of each product were considered to establish 
the amount of green tea present in each bag or the amount of green tea that is recom-
mended to add to the water. In the absence of these values, the recommendations estab-
lished by the ISO 3103 were followed [48]. 
To estimate the intake of mycotoxins, the highest levels quantified of the detected 
mycotoxins were considered. Mycophenolic acid was not included due to the inexistence 
of a reference value for this compound. 
Regarding the EGCG, the intake values were compared with the no expected hepa-
totoxicity value (800 mg of EGCG per day), according to the EFSA (2018) [18]. EGCG levels 
were gathered by the EFSA and considered the determination of this compound in 100 
samples of green tea [18]. It was assumed that intake levels below the referred no expected 
hepatotoxicity value were associated with health benefits. 
For mycotoxins, margin of exposure (MOE) or hazard quotient (HQ) approaches 
were selected according to the genotoxic and/or carcinogenic potentials of the considered 
toxins. MOE was derived considering the ratio of lower confidence limit of the benchmark 
dose (BMDL10) and a MOE of 10,000 or more was considered to be of low concern for 
public health. For aflatoxin B1 and sterigmatocystin, the BMDL10 values considered were, 
respectively, 0.4 µg/kg bw/day [49] and 0.16 mg/kg bw/day [50]. For the HQ calculations, 
a ratio between the exposure levels and the tolerable daily intake (TDI) values were de-
termined. A tolerable or a nontolerable exposure level was considered if HQ was below 
or above one, respectively. For fumonisin B1 and zearalenone, the TDI values considered 
were 0.1 (EFSA, 2018) and 0.25 µg/kg bw/day [51]. 
All the calculations were performed using the Microsoft® Excel 2016. 
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